期刊
ANGIOLOGY
卷 64, 期 6, 页码 466-480出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0003319712464514
关键词
critical limb ischemia; medical therapy; surgical therapy; endovascular therapy; therapeutic angiogenesis; gene therapy; cell therapy
资金
- National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI-K12 Career Development Award) [K12-HL083772-01]
Critical limb ischemia (CLI) is a severe form of peripheral artery disease associated with high morbidity and mortality. The primary therapeutic goals in treating CLI are to reduce the risk of adverse cardiovascular events, relieve ischemic pain, heal ulcers, prevent major amputation, and improve quality of life (QoL) and survival. These goals may be achieved by medical therapy, endovascular intervention, open surgery, or amputation and require a multidisciplinary approach including pain management, wound care, risk factors reduction, and treatment of comorbidities. No-option patients are potential candidates for the novel angiogenic therapies. The application of genetic, molecular, and cellular-based modalities, the so-called therapeutic angiogenesis, in the treatment of arterial obstructive diseases has not shown consistent efficacy. This article summarizes the current status related to the management of patients with CLI and discusses the current findings of the emerging modalities for therapeutic angiogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据